{"nctId":"NCT03905694","briefTitle":"A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1","startDateStruct":{"date":"2019-04-22","type":"ACTUAL"},"conditions":["Primary Hyperoxaluria","Primary Hyperoxaluria Type 1 (PH1)"],"count":18,"armGroups":[{"label":"Lumasiran","type":"EXPERIMENTAL","interventionNames":["Drug: Lumasiran"]}],"interventions":[{"name":"Lumasiran","otherNames":["ALN-GO1"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has genetic confirmation of primary hyperoxaluria type 1 (PH1)\n* Meets urinary oxalate excretion requirements\n* If taking Vitamin B6 (pyridoxine), must have been on stable regimen for at least 90 days\n\nExclusion Criteria:\n\n* If \\<12 months old at screening, has an abnormally high serum creatinine\n* If ≥12 months old at screening, has an estimated glomerular filtration rate (GFR) of ≤45 mL/min/1.73m\\^2\n* Clinical evidence of systemic oxalosis\n* History of kidney or liver transplant","healthyVolunteers":false,"sex":"ALL","minimumAge":"0 Years","maximumAge":"5 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage Change in Spot Urinary Oxalate:Creatinine Ratio From Baseline to Month 6","description":"Percent change in spot urinary oxalate:creatinine ratio was estimated by an average percent change from baseline across Months 3 through 6. A negative change from Baseline indicates a favorable outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-71.97","spread":"2.706"}]}]}]},{"type":"SECONDARY","title":"Percentage Change in Spot Urinary Oxalate: Creatinine Ratio in the Extension Period (Month 6 to End of Study [Month 60])","description":"A negative change from baseline indicates a favorable outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-74.48","spread":"4.246"}]}]}]},{"type":"SECONDARY","title":"Percentage of Time That Spot Urinary Oxalate: Creatinine Ratio is at or Below the Near-normalization Threshold (≤1.5 × Upper Limit of Normal (ULN) for Age)","description":"Percentage of time that spot urinary oxalate: creatinine (UOx:Cr) ratio level is at or below ≤ 1.5xULN is calculated as (cumulative months at or below near normalization threshold divided by cumulative months of assessments)\\*100. Cumulative months in near-normalization is defined as the summation across all intervals that met the near-normal threshold and cumulative months of valid assessments is defined as the summation across all valid post-baseline collections. ULN levels of spot urinary oxalate to creatinine ratio where urine oxalate levels were analyzed using enzymatic assay. The age-dependent reference ULN levels of spot urinary oxalate to creatinine ratio are as follows: 1-1.5 years=0.158; 1.5-2 years=0.138; 2-2.5 years=0.124; 2.5-3 years=0.116; 3-3.5 years=0.102; 3.5-4 years=0.094; 4-4.5 years=0.088; 4.5-5 years=0.082; 5-5.5 years=0.077; 5.5-6 years=0.073.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.95","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Spot Urinary Oxalate: Creatinine Ratio From Baseline","description":"The absolute change is represented as ratio of millimoles of urinary oxalate to millimoles of urinary creatinine.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4880","spread":"0.09127"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5179","spread":"0.09929"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Spot Urinary Oxalate: Creatinine Ratio Levels ≤ the ULN for Age","description":"The percentage of participants meeting the criteria (UOx:Cr ratio ≤ the ULN for age) at least at one post-baseline visit were reported for this outcome measure. The age-dependent reference ULN levels of spot urinary oxalate to creatinine ratio are as follows: 1-1.5 years=0.158; 1.5-2 years=0.138; 2-2.5 years=0.124; 2.5-3 years=0.116; 3-3.5 years=0.102; 3.5-4 years=0.094; 4-4.5 years=0.088; 4.5-5 years=0.082; 5-5.5 years=0.077; 5.5-6 years=0.073.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Spot Urinary Oxalate: Creatinine Ratio Levels ≤ 1.5xULN for Age","description":"The percentage of participants meeting the criteria (UOx:Cr ratio ≤ 1.5xULN for age) at least at one post-baseline visit were reported for this outcome measure. The age-dependent reference ULN levels of spot urinary oxalate to creatinine ratio are as follows: 1-1.5 years=0.158; 1.5-2 years=0.138; 2-2.5 years=0.124; 2.5-3 years=0.116; 3-3.5 years=0.102; 3.5-4 years=0.094; 4-4.5 years=0.088; 4.5-5 years=0.082; 5-5.5 years=0.077; 5.5-6 years=0.073.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change in Plasma Oxalate From Baseline to End of Study (Month 60)","description":"The lower limit of quantification (LLOQ) was 5.55 micromoles per liter (μmol/L). A negative change from baseline indicates a favorable outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.06","spread":"6.711"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.78","spread":"12.814"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Plasma Oxalate From Baseline to End of Study (Month 60)","description":"The LLOQ was 5.55 μmol/L. A negative change from Baseline indicates a favorable outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.03","spread":"1.294"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.03","spread":"1.859"}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Plasma Concentration (Cmax) of Lumasiran","description":"Cmax was the maximum plasma concentration post-dose within the pharmacokinetic (PK) sampling time frame. Higher Cmax generally indicates higher drug exposure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"886","spread":"58.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"869","spread":"84.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1180","spread":"83.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"878","spread":"94.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"790","spread":"91.9"}]}]}]},{"type":"SECONDARY","title":"Time to Maximum Observed Plasma Concentration (Tmax) of Lumasiran","description":"Tmax was estimated by calculating the time required to reach the maximum plasma concentration (Cmax) after the drug administration. Lower Tmax generally indicates faster drug absorption from the administration site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.73","spread":null}]}]}]},{"type":"SECONDARY","title":"Elimination Half-life (t1/2beta) of Lumasiran","description":"Elimination half-life was estimated from the terminal phase of the plasma concentration-time profile post-dose. Shorter half-life generally indicates rapid drug elimination from the body.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.99","spread":null}]}]}]},{"type":"SECONDARY","title":"Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24) of Lumasiran","description":"AUC0-24 was the total drug exposure calculated as the area under the plasma concentration-time curve from the time of dosing (t = 0) to 24 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8050","spread":"37.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8450","spread":"41.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10800","spread":"39.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8420","spread":"57.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7420","spread":"61.6"}]}]}]},{"type":"SECONDARY","title":"Area Under the Concentration-time Curve From 0 to Last Quantifiable Concentration (AUC0-last) of Lumasiran","description":"AUC0-last was the total drug exposure calculated as the area under the plasma concentration-time curve from time 0 to the time of the last measurable (quantifiable) concentration (C\\_last).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7870","spread":"33.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6620","spread":"95.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8480","spread":"76.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5770","spread":"155.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7100","spread":"80.0"}]}]}]},{"type":"SECONDARY","title":"Area Under the Concentration-time Curve From 0 to Infinity (AUC0-infinity) of Lumasiran","description":"AUC0-infinity was the total drug exposure estimated as the area under the plasma concentration-time curve from time 0 extrapolated to infinity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9180","spread":"31.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8840","spread":"40.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11900","spread":"29.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11600","spread":"48.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9610","spread":"48.8"}]}]}]},{"type":"SECONDARY","title":"Apparent Clearance (CL/F) of Lumasiran","description":"Apparent clearance was calculated by dividing the area under the plasma concentration-time curve from zero infinity by the dose administered. A higher clearance generally indicates faster elimination from the body.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.62","spread":"24.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":"32.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.06","spread":"28.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.87","spread":"30.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.22","spread":"37.7"}]}]}]},{"type":"SECONDARY","title":"Apparent Volume of Distribution (V/F) of Lumasiran","description":"Apparent Volume of Distribution generally indicates the extent of drug distribution in the body.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.2","spread":"69.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":"71.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":"75.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.1","spread":"107.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.6","spread":"70.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)","description":"eGFR \\[in milliliters per minute per 1.73 meters square (mL/min/1.73m\\^2)\\] was calculated from serum creatinine (SCr) based on the Schwartz Bedside Formula for participants ≥12 months of age at the time of assessment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.263","spread":"3.8461"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.525","spread":"4.8873"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs)","description":"An Adverse Event (AE) is any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":18},"commonTop":["Pyrexia","Vomiting","Gastroenteritis","Rhinitis","Upper respiratory tract infection"]}}}